NRx Pharmaceuticals (NASDAQ:NRXP) Announces Quarterly Earnings Results, Misses Estimates By $0.10 EPS

NRx Pharmaceuticals (NASDAQ:NRXP) announced its quarterly earnings results on Friday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10), Zacks reports.

NRx Pharmaceuticals Stock Up 13.5 %

Shares of NRXP opened at $2.35 on Friday. NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $6.01. The company has a 50 day moving average of $3.02 and a 200-day moving average of $2.02. The stock has a market capitalization of $39.75 million, a P/E ratio of -1.10 and a beta of 1.22.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Friday. D. Boral Capital reissued a “buy” rating and set a $31.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday, January 28th. Finally, Ascendiant Capital Markets boosted their price objective on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, December 2nd.

Insider Activity at NRx Pharmaceuticals

In other news, Chairman Jonathan C. Javitt acquired 40,000 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The stock was bought at an average price of $1.17 per share, with a total value of $46,800.00. Following the transaction, the chairman now directly owns 84,634 shares in the company, valued at approximately $99,021.78. The trade was a 89.62 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 19.00% of the stock is owned by insiders.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.